8-K: Philip Morris International Holds 2024 Annual Meeting, Highlights Smoke-Free Progress

Philip Morris International held its 2024 Annual Meeting of Shareholders, showcasing strong progress in its smoke-free transformation and business performance.

Summary

• Philip Morris International (PMI) conducted its 2024 Annual Meeting of Shareholders on May 8, 2024.
• The meeting included presentations from the Executive Chairman and CEO, covering the company's 2023 performance and the start of 2024.
• PMI highlighted its robust business fundamentals and rapid progress in its smoke-free transformation.
• The company noted excellent momentum in the heat-not-burn and nicotine pouch categories.
• PMI's smoke-free products reached nearly 40% of total net revenues and over 40% of gross profit in the fourth quarter of 2023.
• Approximately 80% of shares entitled to vote were represented at the meeting.
• Shareholders elected 12 directors, approved executive compensation, and ratified the selection of PricewaterhouseCoopers SA as independent auditors.
• The company's smoke-free products are available in 84 markets, with an estimated 33 million adult users worldwide.
• PMI has invested over $12.5 billion since 2008 in developing and commercializing smoke-free products.
• The company aims to expand into wellness and healthcare through its Vectura Fertin Pharma business.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the company's progress in its smoke-free transformation and business performance, but also acknowledges several risks and uncertainties.

Positives

• PMI is making strong progress in its smoke-free transformation.
• The company has excellent momentum in the heat-not-burn and nicotine pouch categories.
• PMI is committed to rewarding shareholders over time.
• The company has received continued recognition by leading external stakeholders for its sustainability efforts.
• PMI has a strong foundation and significant expertise in life sciences.

Negatives

• The document highlights several business risks including excise tax increases, regulatory restrictions, health concerns, litigation, and intense competition.
• PMI's future profitability may be adversely affected if it is unsuccessful in its attempts to grow smoke-free products or if regulation does not differentiate between such products and cigarettes.
• The company is subject to the lower predictability of its smoke-free products performance.

Risks

• PMI faces risks from excise tax increases and discriminatory tax structures.
• Increasing marketing and regulatory restrictions could reduce competitiveness.
• Health concerns related to tobacco and nicotine use pose a risk.
• The company is subject to litigation related to tobacco and intellectual property.
• Intense competition in the market is a significant risk.
• Global and individual country economic, regulatory, and political developments can impact the business.
• The impact of Russia's invasion of Ukraine is a risk factor.
• Changes in adult smoker behavior can affect PMI's performance.
• Natural disasters and pandemics can disrupt the business.
• Counterfeiting, contraband, and cross-border purchases can lead to lost revenues.
• Governmental investigations pose a risk.
• Unfavorable currency exchange rates and currency devaluations can impact profitability.
• Adverse changes in corporate tax laws can affect the company.
• Changes in the cost, availability, and quality of tobacco and other raw materials are a risk.
• The integrity of information systems and data privacy policies are crucial.
• PMI's ability to introduce, commercialize, and grow smoke-free products is a risk.
• The company's ability to expand its brand portfolio and enter new markets is a risk.
• Attracting and retaining talent is a challenge.
• Integrating recent transactions and acquisitions successfully is a risk.

Future Outlook

The company aims to further accelerate its smoke-free transformation and expand into wellness and healthcare areas. PMI is committed to rewarding shareholders over time.

Management Comments

• Jacek Olczak, Chief Executive Officer, stated that the company's strategy to become a smoke-free company has enabled them to build and sustain strong momentum.
• Jacek Olczak also mentioned that as a global smoke-free champion with leading brands IQOS and ZYN, they are well positioned to further accelerate their transformation.

Industry Context

PMI's focus on smoke-free products aligns with the broader industry trend of shifting away from traditional cigarettes towards reduced-risk alternatives. The acquisition of Swedish Match and the development of IQOS and ZYN position PMI as a leader in this evolving market.

Comparison to Industry Standards

• PMI's investment of $12.5 billion in smoke-free products since 2008 is a significant commitment compared to some competitors.
• The company's 37% revenue share from smoke-free products in 2023 is a strong indicator of progress in the industry.
• The availability of PMI's smoke-free products in 84 markets demonstrates a wide global reach.
• The estimated 33 million adult users of PMI's smoke-free products is a substantial user base.
• The FDA authorization of versions of PMI's IQOS devices and Swedish Match's General snus as Modified Risk Tobacco Products is a significant achievement.

Stakeholder Impact

• Shareholders are positively impacted by the company's commitment to rewarding them over time.
• Employees are impacted by the company's focus on attracting and retaining talent.
• Customers are impacted by the company's focus on developing and commercializing innovative smoke-free products.
• Public health is impacted by the company's efforts to reduce the harm caused by smoking.

Next Steps

• PMI will file a Form 8-K with the SEC in the coming days with final voting results.
• An archived copy of the webcast of the meeting will be available for approximately one year.
• The presentation slides and script will be available at www.virtualshareholdermeeting.com/PM2024.

Key Dates

Keywords

Philip Morris International, smoke-free products, IQOS, ZYN, Annual Meeting, shareholders, tobacco, nicotine, heat-not-burn, sustainability, PricewaterhouseCoopers, Vectura Fertin Pharma